Medical interventions for the prevention of platinum-induced hearing loss in children with cancer

Keyphrases

• Children with Cancer 100%
• Ototoxicity 100%
• Medical Intervention 100%
• Hearing Loss in children 100%
• Amifostine 60%
• Cisplatin 50%
• Adverse Effects 50%
• Platinum Therapy 50%
• Additional Treatment 50%
• Sodium Thiosulfate 50%
• Hepatoblastoma 40%
• Randomized Controlled Trial 40%
• Hearing Impairment 40%
• Common Toxicity Criteria 40%
• Osteosarcoma 40%
• Number of Participants 40%
• National Cancer Institute 40%
• Confidence Interval 30%
• Carboplatin 30%
• Quality of Life 30%
• Risk Ratio 30%
• Malignancy 20%
• Placebo 20%
• Tumor Response 20%
• Controlled Experiment 20%
• Intra-arterial Cisplatin 20%
• Pediatric Oncology 10%
• Cancer Mortality 10%
• Pediatric Malignancy 10%
• International Society 10%
• Selection Criteria 10%
• Treatment Complications 10%
• Event-free Survival 10%
• Overall Survival 10%
• PubMed 10%
• Embase 10%
• Antitumor Efficacy 10%
• Disease Progression 10%
• Cardiotoxicity 10%
• MEDLINE 10%
• Data Extraction 10%
• Cochrane 10%
• Recent Update 10%
• Toxicity Grades 10%
• Pediatric Hematology 10%
• Oxaliplatin 10%
• Vomiting 10%
• Tinnitus 10%
• Partial Response 10%
• Complete Response 10%
• Partial Remission 10%
• One-child 10%
• End of Treatment 10%
• Risk of Bias Assessment 10%
• Ongoing Trials 10%
• Ovid 10%
• World Health Organization 10%
• International Clinical Trials Registry Platform (ICTRP) 10%
• Conference Proceedings 10%
• Review Authors 10%
• Cochrane Central Register of Controlled Trials 10%
• Disease Relapse 10%
• High-quality Research 10%
• International Conference 10%
• Long-term Complications 10%
• Platinum Analogs 10%
• Search Methods 10%
• Dosage Schedule 10%
• Cochrane Review 10%
• Second Primary Cancer 10%
• Efficacy-toxicity 10%
• WHO ICTRP 10%
• Grade Estimation 10%
• Loss of Life 10%
• Certainty of Evidence 10%
• Progression Disease 10%
• Hearing Quality 10%
• Renal Toxicity 10%
• American Society 10%

Medicine and Dentistry

• Malignant Neoplasm 100%
• Ototoxicity 100%
• Hearing Impairment 100%
• Medical Intervention 100%
• Cisplatin 70%
• Amifostine 60%
• Adverse Event 50%
• Sodium Thiosulfate 50%
• Randomized Controlled Trial 40%
• Hepatoblastoma 40%
• Osteosarcoma 40%
• Carboplatin 30%
• Quality of Life 30%
• Neoplasm 20%
• Childhood Cancer 20%
• Cancer 20%
• Controlled Clinical Trial 20%
• Placebo 20%
• Clinical Trial 10%
• Disease 10%
• Oncology 10%
• Cancer Mortality 10%
• Second Cancer 10%
• Event Free Survival 10%
• Complication of Treatment 10%
• Overall Survival 10%
• Systematic Review 10%
• Platinum Derivative 10%
• Disease Exacerbation 10%
• Cardiotoxicity 10%
• Tinnitus 10%
• Pediatric Hematology 10%
• Nephrotoxicity 10%
• Oxaliplatin 10%
• Drug Dose Regimen 10%
• Adolescence 10%

Pharmacology, Toxicology and Pharmaceutical Science

• Malignant Neoplasm 100%
• Ototoxicity 100%
• Hearing Impairment 100%
• Cisplatin 70%
• Amifostine 60%
• Adverse Event 50%
• Sodium Thiosulfate 50%
• Hepatoblastoma 40%
• Randomized Controlled Trial 40%
• Osteosarcoma 40%
• Carboplatin 30%
• Neoplasm 20%
• Childhood Cancer 20%
• Placebo 20%
• Controlled Clinical Trial 20%
• Clinical Trial 10%
• Disease 10%
• Event Free Survival 10%
• Overall Survival 10%
• Remission 10%
• Platinum Derivative 10%
• Disease Exacerbation 10%
• Cardiotoxicity 10%
• Cancer Mortality 10%
• Oxaliplatin 10%
• Tinnitus 10%
• Nephrotoxicity 10%
• Second Cancer 10%